Daiichi Sankyo studies show Welchol can lower A1C levels
PARSIPPANY, N.J. Daiichi Sankyo has released data from post-hoc analyses of three pivotal studies involving its cholesterol drug Welchol and diabetes.
The data showed that adding Welchol to common diabetes treatment regimens can lower A1C in patients with Type 2 diabetes mellitus by 1 percent or greater. Almost 50 percent of the patients in the analyses had a mean reduction in A1C of 1.04 percent and nearly a quarter had a mean reduction as great as 1.40 percent.
A second post-hoc analysis demonstrated that Welchol lowered A1C and LDL-cholesterol levels consistently across type 2 diabetes patients, regardless of age, gender or race. These findings were included among five poster presentations by Daiichi Sankyo at the National Lipid Association Annual Scientific Sessions.
“These findings are significant given the critical importance of achieving and maintaining A1C control,” said Vivian Fonseca, professor of Medicine and Pharmacology and chief section chief of Endocrinology at Tulane University Health Sciences Center, and a principal study investigator. “A patient’s A1C level is one of our primary markers in determining their risk of developing cardiovascular disease. These analyses show that adding Welchol to the most common type 2 diabetes regimens can help achieve additional A1C lowering across many different patient types.”
Bystolic fulfills pharmacists’ desire for a new beta-blocker
NEW YORK Forest Laboratories and Mylan’s new, once-daily hypertension drug Bystolic now is available in pharmacies nationwide.
A recent survey showed that out of 20,000 retail pharmacists, 78 percent felt there was a need for a beta-blocker with an improved tolerability profile.
More than 2,000 people received Bystolic (nebivolol) during clinical trials. The drug’s efficacy was similar to that of other approved beta-blockers, the FDA said. The most common reported side effects were headache, fatigue, dizziness and diarrhea.
Hypertension affects about 72 million adults in America.
Tenn. pharmacy school receives $600,000 grant
NASHVILLE, Tenn. Lipscomb University has received a $600,000 grant from The Memorial Foundation to support the school’s new $10.1 million pharmacy school, which will receive its first class in August, according to published reports. The Lipscomb College of Pharmacy has accepted 75 students in its first class.
The money will be used to build three patient support laboratories where students will learn to compound and prepare drugs, carry out experiments and examine and assess patients.
The school will be located in the Burton Health Sciences Center. In honor of the foundation’s grant the labs will be named The Memorial Foundation Pharmacy Practice Center.
“We believe it is a good investment for the community and for those students who want to prepare for a career in pharmacy,” said J.D. Elliott, president of The Memorial Foundation.